Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Director Geoffrey M. Duyk sold 41,591 shares of the firm’s stock in a transaction that occurred on Wednesday, February 15th. The stock was sold at an average price of $46.63, for a total transaction of $1,939,388.33. Following the transaction, the director now directly owns 10,067 shares of the company’s stock, valued at $469,424.21. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) traded down 4.15% during trading on Thursday, hitting $45.00. The stock’s market capitalization is $1.50 billion. Aerie Pharmaceuticals, Inc. has a one year low of $10.82 and a one year high of $47.57. The firm has a 50 day moving average price of $42.28 and a 200 day moving average price of $34.57.

“Geoffrey M. Duyk Sells 41,591 Shares of Aerie Pharmaceuticals, Inc. (AERI) Stock” was first reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this news story can be viewed at http://www.dailypolitical.com/2017/02/16/geoffrey-m-duyk-sells-41591-shares-of-aerie-pharmaceuticals-inc-aeri-stock.html.

A number of institutional investors have recently modified their holdings of AERI. Tocqueville Asset Management L.P. raised its position in shares of Aerie Pharmaceuticals by 1.7% in the second quarter. Tocqueville Asset Management L.P. now owns 42,300 shares of the company’s stock valued at $744,000 after buying an additional 725 shares during the period. Nationwide Fund Advisors raised its position in shares of Aerie Pharmaceuticals by 3.2% in the second quarter. Nationwide Fund Advisors now owns 79,473 shares of the company’s stock valued at $1,399,000 after buying an additional 2,490 shares during the period. Sectoral Asset Management Inc. acquired a new position in shares of Aerie Pharmaceuticals during the second quarter valued at about $1,556,000. Iguana Healthcare Management LLC raised its position in shares of Aerie Pharmaceuticals by 100.0% in the second quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the company’s stock valued at $2,640,000 after buying an additional 75,000 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in shares of Aerie Pharmaceuticals by 16.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,893 shares of the company’s stock valued at $315,000 after buying an additional 2,544 shares during the period. 95.69% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on the stock. Aegis reaffirmed a “buy” rating and set a $63.00 price target on shares of Aerie Pharmaceuticals in a research note on Thursday, November 10th. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 3rd. Canaccord Genuity reaffirmed a “buy” rating and set a $50.00 price target on shares of Aerie Pharmaceuticals in a research note on Tuesday, December 20th. JMP Securities reaffirmed an “outperform” rating and set a $49.00 price target on shares of Aerie Pharmaceuticals in a research note on Friday, December 23rd. Finally, Royal Bank Of Canada raised their target price on shares of Aerie Pharmaceuticals from $48.00 to $49.00 and gave the company an “outperform” rating in a research note on Friday, October 28th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $51.67.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.